The renal effects of the water-soluble, non-folylpolyglutamate synthetase-dependent thymidylate synthase inhibitor ZD9331 in mice
1998

Effects of ZD9331 on Kidney Function in Mice

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): Ml Walton, F Mitchell, GW Aherne, CJ Medlow, FT Boyle, AL Jackman

Primary Institution: CRC Cancer Therapeutics Centre, Institute of Cancer Research

Hypothesis

ZD9331, a thymidylate synthase inhibitor, will show non-nephrotoxic effects at therapeutic doses in mice.

Conclusion

ZD9331 is non-nephrotoxic at active anti-tumour doses in mice, but high doses can impair renal function depending on the route of administration.

Supporting Evidence

  • ZD9331 showed no effect on renal function at doses up to 150 mg kg-1.
  • At 200 mg kg-1, renal function was significantly inhibited following intravenous administration.
  • Pharmacokinetic studies indicated higher plasma drug concentrations with intravenous dosing.

Takeaway

This study tested a new cancer drug in mice to see if it hurts their kidneys. It found that the drug is safe for the kidneys at normal doses but can cause problems at very high doses.

Methodology

Mice were given ZD9331 via different routes, and kidney function was assessed by measuring glomerular filtration rate using [14C]inulin clearance.

Limitations

The study was conducted in mice, which may not fully represent human responses.

Participant Demographics

Adult female DBA-2 mice, aged 8-12 weeks, weighing 15-25 g.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication